MNG407
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.508
- TGF_BETA_SIGNALING+0.453
- ESTROGEN_RESPONSE_EARLY+0.353
- HYPOXIA+0.337
- ANDROGEN_RESPONSE+0.323
- ESTROGEN_RESPONSE_LATE+0.284
- APOPTOSIS+0.269
- PROTEIN_SECRETION+0.255
- UV_RESPONSE_DN+0.217
- APICAL_JUNCTION+0.204
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.316
- OXIDATIVE_PHOSPHORYLATION-0.259
- ANGIOGENESIS-0.253
- WNT_BETA_CATENIN_SIGNALING-0.146
- FATTY_ACID_METABOLISM-0.141
- ADIPOGENESIS-0.111
- E2F_TARGETS-0.099
- MYC_TARGETS_V2-0.096
- CHOLESTEROL_HOMEOSTASIS-0.071
- PANCREAS_BETA_CELLS-0.062
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG401 | — | — | 0.764 |
| 2 | MNG901 | — | — | 0.754 |
| 3 | MNG902 | — | — | 0.730 |
| 4 | MNG20 | — | — | 0.692 |
| 5 | MNG405 | — | — | 0.686 |
| 6 | MNG1059 | — | — | 0.681 |
| 7 | MNG932 | — | — | 0.647 |
| 8 | MNG462 | — | — | 0.629 |
| 9 | BS_KP735TJ6 | high-grade glioma | — | 0.629 |
| 10 | TCGA-CN-6998-01A-23R-2016-07 | — | — | 0.627 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.508 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.453 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.353 | Inavolisib | — uncovered |
| HYPOXIA | 0.337 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.323 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.284 | Idelalisib | — uncovered |
| APOPTOSIS | 0.269 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.255 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.217 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.204 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.192 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.188 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.183 | Temsirolimus | — uncovered |
| P53_PATHWAY | 0.161 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.156 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.152 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.141 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.140 | Temsirolimus | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.106 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.104 | Inavolisib | — uncovered |